How Disintermediation Is Being Managed in Rx Models

Why It Matters

Consolidating fragmented pharmacy data into a single, finance‑ready view enables employers to control spend, validate guarantees, and negotiate renewals with confidence, reshaping the PBM market dynamics.

Key Takeaways

• Transparent PBM use hit 31% in 2025, up from 12% in 2024.
• Employers unbundle traditional PBM models, adopting multi‑vendor pharmacy configurations.
• Neutral‑optimization layers merge claims, rebates, and clinical data into a single view.
• Brokers must verify savings calculations and ensure employer access to reports.
• Targeting duplicate therapy, polypharmacy, and biosimilar switches cuts wasteful spend.

Pulse Analysis

The shift toward disintermediation reflects employers’ desire for greater transparency and control over drug spend. By unbundling the monolithic PBM model, they can negotiate specialty carve‑outs, add clinical navigation partners, and select best‑in‑class vendors for each function. However, this flexibility introduces data silos—claims files, rebate reconciliations, and utilization reports arrive on different timelines and formats, making it difficult to produce a coherent, renewal‑ready cost narrative.

Neutral‑optimization layers have emerged as the connective tissue that reconciles these disparate streams. Leveraging physician‑directed analytics, they identify therapeutic equivalents, biosimilar opportunities, and waste patterns such as duplicate therapy or polypharmacy. The resulting recommendations flow through prescribers, generating documented savings that can be directly tied to financial guarantees. For brokers, this translates into a single dashboard that quantifies net cost drivers, validates rebate performance, and supplies the hard numbers needed for renewal negotiations.

For the broader market, the rise of neutral optimization signals a maturing pharmacy benefits ecosystem where accountability is shared across multiple partners but measured through a unified lens. Employers gain a clearer picture of where spend is concentrated and how targeted interventions impact the bottom line. Brokers, in turn, can differentiate themselves by delivering finance‑ready proof rather than fragmented spreadsheets, positioning themselves as strategic advisors in an increasingly competitive benefits landscape.